Objective: The aim of this study was to survey the use of antipsychotic polypharmacy (APP) in older Asian patients with schizophrenia and examine its demographic and clinical correlates.
S chizophrenia is a severe psychiatric disorder that results in approximately 20% reduction in life expectancy compared to the general population. 1, 2 In recent decades, with the general improvement of mental health care and judicious maintenance antipsychotic treatment, the mortality has been lowered, 3, 4 enabling many patients with schizophrenia to live into older adulthood. 5 In contrast to younger patients, older patients with schizophrenia are a special population characterized with different psychopathology, higher likelihood of drug-induced adverse effects and poor general health. 6, 7 Although guidelines for the treatment of schizophrenia consistently recommend antipsychotic monotherapy (AMP) and suggest antipsychotic polypharmacy (APP: the concurrent use of 2 or more antipsychotic drugs) only as a last resort, 8, 9 APP is still common in clinical practice. It is estimated that APP typically ranges from 10% to 30% in schizophrenia depending on the patient population, treatment setting, and methods used for operationalizing polypharmacy.
10Y12
To the best of our knowledge, there has been no large-scale study examining the use of APP in older patients with schizophrenia. We conducted a secondary analysis of the data from the Research on Asian Psychotropic Prescription Patterns (REAP) project in this study and sought to explore the frequency of APP in older Asian patients with schizophrenia and to determine its demographic and clinical correlates. Given the well-known low tolerability to psychotropic drugs, the age-related renal and hepatic dysfunctions and their effects on pharmacokinetics and pharmacodynamics, we hypothesized that only a small proportion of older patients with schizophrenia would receive APP in clinical practice.
MATERIALS AND METHODS

Settings, Study Design, and Subjects
The study was part of the REAP project, a pharmacoepidemiological project of psychotropic drug prescription trends in schizophrenic inpatients in Asia. The REAP was initially conducted in July 2001 followed by 2 waves of studies in July 2004
and October 2008 to March 2009 using the same design and standardized protocol. Consensus meetings on data collection and uniformity of data entry were held before each survey. The participating countries and territories include mainland China (China hereafter), Hong Kong, Japan, Korea, Singapore, and Taiwan. Centers in India, Malaysia, and Thailand joined the surveys in 2009. Details of the REAP project have been described elsewhere. 13, 14 Patients were enrolled in this study if they met the following criteria: (1) International Statistical Classification of Diseases, 10th Revision or Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition schizophrenia; (2) age of 55 years or older; (3) taking antipsychotic drugs; and (4) ability to understand the study aims. Patients having major medical conditions were excluded. Doses of antipsychotic drugs were converted into chlorpromazine equivalent milligrams, 15Y17 and the total dose of antipsychotics is the sum of every antipsychotic drug.
Eligible patients were recruited consecutively, and their sociodemographic and clinical characteristics including age, sex, length of illness, type and doses of antipsychotics, presence or absence of significant psychotic symptoms in the past month, and extrapyramidal adverse effects (EPS) were collected by a review of medical records in 2001 and by either a review of medical records only or a review of medical records supplemented by a patient interview in 2004 and 2009 using a questionnaire designed for the study. Tardive dyskinesia is treated separately from the other forms of EPS because of its phenomenological and treatment characteristics. The data were collected by the attending psychiatrists or by members of the research team with the agreement of the psychiatrist in charge of the patient.
The study was approved by the clinical research ethics committees of the respective centers. Given the anonymous nature of this observational study and minimal risk to patients, the patients' informed consent was exempted in some participating study sites according to the requirements of the local clinical research ethics committee 18 if only a review of case notes was used. All patients receiving the interview provided written or oral consent according to the requirements of the clinical research ethics committee in the respective study sites. The requirements of the clinical research ethics committee usually vary on a local basis across different study sites.
Statistical Analysis
The data were analyzed using Statistical Package for the Social Sciences version 13.0 for Windows. Comparisons between the 3 surveys with respect to APP prescribing patterns were made with W 2 tests. Multiple logistic regression analysis with the ''Enter'' method was used to determine the demographic and clinical variables influencing APP. Cross-sectional APP use was the dependent variable, whereas independent variables included study sites and time, age, sex, psychopathology, length of illness, use of first-generation antipsychotics (FGAs), dose of antipsychotics, and the presence of EPS and tardive dyskinesia. The level of significance was set at P = 0.05 (2-tailed). T1 Table 1 presents the sociodemographic and clinical characteristics of the whole sample and separately for patients by study site. 
RESULTS
Altogether
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the use of APP in participating countries and regions over the study period. Table 2 displays the prescribing patterns of antipsychotic drugs prescribed in the 3 surveys. The combination of FGAs decreased, whereas the combinations of second-generation antipsychotics (SGAs) and those of FGAs and SGAs increased over time. Table 3 presents the factors that were independently associated with APP. Patients on APP had a higher dose of antipsychotics and were more likely to receive FGAs than those prescribed antipsychotic monotherapy.
T2
T3
DISCUSSION
To the best of our knowledge, this was the first international study investigating the use of APP in older Asian patients with schizophrenia. The hypothesis that only a small proportion of older patients with schizophrenia would receive APP was not supported. Surprisingly, 51.6% of the patients were prescribed APP, a figure significantly higher than the 10% to 30% for Western patients with schizophrenia. 11, 12 Our result is also considerably higher than earlier findings in Asia. 19, 20 For example, in a random sample of 398 Chinese schizophrenic outpatients aged between 18 and 60 years, 17.6% were on APP. 19 There was considerable variation in APP prescription in different study sites varying from 17.5% in Taiwan to 65.9% in Japan.
There are 2 possible reasons for the common use of APP in Asian countries. First, inpatients usually present with more severe symptoms and are more likely to be treatment resistant, which could increase APP use. Second, there is a widely held belief in Asian countries that a combination of medications with different pharmacological components is more effective. 21 It should be noted that there is only weak evidence at best supporting improved efficacy with APP, whereas it could increase adverse effects, mortality, and cost of treatment and reduce treatment adherence.
22Y24 Therefore, strategies recommended by treatment guidelines consistently discourage APP. 8, 9, 25 Considering the higher prevalence of somatic comorbidity in elderly patients with schizophrenia resulting in frequent use of concomitant medications and also the age-related reduced drug clearance of antipsychotics and decreased dopamine receptor reserve, 7, 26, 27 APP should be used sparingly in this patient population. Taken together, the rationale of the common use of APP in older Asian patients with schizophrenia should be reexamined.
Recent studies suggest that physical and psychosocial factors influence treatment response in later life; therefore, both the drug industry and researchers need to further clarify the impact of old age on pharmacologic properties of psychotropic Multiple logistic regression analysis with antipsychotic monotherapy as the reference group.
Centers in India, Malaysia, and Thailand joined the survey in 2009; therefore, they were not included in multiple logistic regression analysis. There was colinearity between the use of FGA and SGA; therefore, the use of SGA was not included in multiple logistic regression analysis. drugs and enact treatment guidelines for this population. 6 A recent study found that most patients with schizophrenia on APP, even those with persistent psychotic symptoms, tolerated well the switch from APP to AMP, thereby reducing weight gain and EPS. 28 These data support prescribing guidelines that encourage trials of AMP for patients receiving APP. 8, 9 In this study, the frequencies of APP were comparable across the 3 surveys (58.4%, 48.9%, and 47.7% in 2001, 2004, and 2009), but the proportion of APP involving SGAs (FGAs + SGAs, or SGAs + SGAs) increased over time. The shift toward more APP involving SGAs (FGAs + SGAs, or SGAs + SGAs) over the past 9 years may be driven by the assumed favorable effects on refractory symptoms, lower risk of EPS, and the declining costs of SGAs. However, recent studies failed to find significant difference between FGAs and SGAs in efficacy; at the same time, some SGAs increase the risk of diabetes mellitus, cause weight gain and metabolic syndrome, and add substantial costs to the treatment.
29Y31
In line with a recent study, 32 a multivariate analysis showed that patients on APP had higher doses of antipsychotics. More frequent use of FGAs in patients on APP could be explained by the fact that FGAs are affordable and easily available in Asian countries. The association between APP and FGAs could be also due to the attempt to optimize the dopamine-2 receptor occupancy and to target a variety of receptors beyond the dopamine-2 receptor, 33, 34 although this practice lacks strong evidence. 35, 36 Frequency of APP varied considerably across Asian countries, probably owing to differences in local prescribing and psychopharmacological traditions.
The strengths of this study include its large sample size, the number of participating sites involved, and the standardized assessment. Yet, there are a few limitations that restrict the generalizability of the results. First, the study targeted only inpatients with no major medical conditions in selected Asian countries in this huge continent with a wide variety of sociocultural, economic, and mental health care. Second, some important variables likely to influence APP prescription, such as local prescription guidelines, type of psychiatric facilities, and health insurance policies in participating study centers, were not evaluated owing to logistic reasons. Third, the data were collected by a chart review in 2001 and by either a review of case chart or patient interviews in 2004 and 2009, which might have led to observational bias. Fourth, owing to the cross-sectional design, the causality between the use of APP and demographic and clinical factors, and comparing the efficacy and safety between APP and AMP, could not be explored. Fifth, there are differences in health care schemes, prescribing traditions, treatment guidelines, and characteristics between institutions even within one country, such as China and India. The confounding effects of these differences could not be explored in this study. In addition, the cross-sectional design might lead to overestimated frequency of APP because of the cross-tapering of different antipsychotic medications that would temporarily increase APP. Finally, in this pharmacoepidemiological study with 3 separate independent samples, a small proportion of patients might be repeatedly assessed, although the wide time span between the 3 surveys minimized this possibility.
In conclusion, the results suggest that the prescription of APP for older schizophrenic inpatients in Asia is very common. Continuing education and training addressing the unnecessary use of APP and its potentially hazardous adverse effects is clearly necessary. Controlled trials exploring the efficacy, safety, and tolerability of APP are needed to inform treatment guidelines to advise physicians about the judicious use of APP in this population. 
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